Eton Pharmaceuticals, Inc. (ETON) 10-Year Financial Performance & Capital Metrics

ETON • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Show more

Revenue $39M +23.3%
EBITDA -$1M -398.6%
Net Income -$4M -308.4%
EPS (Diluted) -0.15 -311.0%
Gross Margin 60.01% -9.8%
EBITDA Margin -3.72% -304.4%
Operating Margin -6.66% -76.7%
Net Margin -9.8% -231.3%
ROE -19.16% -192.3%
ROIC -10.01% +84.4%
Debt/Equity 1.22 +250.9%
Interest Coverage -1.30

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 109.8%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high
✗Expensive at 16.3x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y109.83%

3Y21.35%

TTM102.77%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.91%

EPS CAGR

10Y-

5Y-

3Y-

TTM-14.85%

ROCE

10Y Avg-50.51%

5Y Avg-40.95%

3Y Avg-18.02%

Latest-7.25%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	959K	39K	21.83M	21.25M	31.64M	39.01M
Revenue Growth %	-	-	-	-0.96%	558.79%	-0.03%	0.49%	0.23%
Cost of Goods Sold+	13K	63K	453K	286K	2.62M	6.93M	10.58M	15.6M
COGS % of Revenue	-	-	0.47%	7.33%	0.12%	0.33%	0.33%	0.4%
Gross Profit+	-13K	-63K	506K	-247K	19.21M	14.32M	21.06M	23.41M
Gross Margin %	-	-	0.53%	-6.33%	0.88%	0.67%	0.67%	0.6%
Gross Profit Growth %	-	-3.85%	9.03%	-1.49%	78.77%	-0.25%	0.47%	0.11%
Operating Expenses+	7.14M	10.32M	19.11M	26.86M	20.7M	22.58M	22.25M	26.01M
OpEx % of Revenue	-	-	19.92%	688.82%	0.95%	1.06%	0.7%	0.67%
Selling, General & Admin	3.21M	4.69M	7.55M	12.76M	14.47M	18.58M	18.93M	22.75M
SG&A % of Revenue	-	-	7.87%	327.18%	0.66%	0.87%	0.6%	0.58%
Research & Development	3.93M	5.63M	11.55M	14.1M	6.24M	4M	3.32M	3.25M
R&D % of Revenue	-	-	12.05%	361.64%	0.29%	0.19%	0.1%	0.08%
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-7.15M	-10.32M	-18.6M	-27.11M	-1.5M	-8.26M	-1.19M	-2.6M
Operating Margin %	-	-	-19.4%	-695.15%	-0.07%	-0.39%	-0.04%	-0.07%
Operating Income Growth %	-	-0.44%	-0.8%	-0.46%	0.94%	-4.53%	0.86%	-1.18%
EBITDA+	-7.14M	-10.26M	-18.15M	-26.46M	-1.03M	-6.49M	-291K	-1.45M
EBITDA Margin %	-	-	-18.93%	-678.46%	-0.05%	-0.31%	-0.01%	-0.04%
EBITDA Growth %	-	-0.44%	-0.77%	-0.46%	0.96%	-5.28%	0.96%	-3.99%
D&A (Non-Cash Add-back)	13K	63K	447K	651K	462K	1.77M	901K	1.15M
EBIT	-7.16M	-10.32M	-18.6M	-27.11M	-1.5M	-8.26M	-1.19M	-2.6M
Net Interest Income+	0	0	281K	-889K	0	0	0	-2M
Interest Income	52.5K	164K	281K	0	0	0	0	0
Interest Expense	0	0	0	889K	0	0	0	2M
Other Income/Expense	-6K	-2.42M	281K	-859K	-460K	-761K	503K	-1.21M
Pretax Income+	-7.16M	-12.74M	-18.32M	-27.97M	-1.96M	-9.02M	-689K	-3.81M
Pretax Margin %	-	-	-19.1%	-717.18%	-0.09%	-0.42%	-0.02%	-0.1%
Income Tax+	0	0	0	0	0	0	247K	15K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1.36%	1%
Net Income+	-7.16M	-12.74M	-18.32M	-27.97M	-1.96M	-9.02M	-936K	-3.82M
Net Margin %	-	-	-19.1%	-717.18%	-0.09%	-0.42%	-0.03%	-0.1%
Net Income Growth %	-	-0.78%	-0.44%	-0.53%	0.93%	-3.61%	0.9%	-3.08%
Net Income (Continuing)	-7.16M	-12.74M	-18.32M	-27.97M	-1.96M	-9.02M	-936K	-3.82M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.41	-1.99	-1.02	-1.33	-0.08	-0.36	-0.04	-0.15
EPS Growth %	-	-3.85%	0.49%	-0.3%	0.94%	-3.64%	0.9%	-3.11%
EPS (Basic)	-0.41	-1.99	-1.02	-1.33	-0.08	-0.36	-0.04	-0.15
Diluted Shares Outstanding	17.46M	6.42M	17.76M	21.01M	25.21M	25.15M	25.65M	25.89M
Basic Shares Outstanding	17.46M	6.42M	17.76M	21.01M	25.21M	25.15M	25.64M	25.89M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.29M	27.5M	15.01M	24.7M	23.6M	20M	26.84M	41.02M
Cash & Short-Term Investments	13.16M	26.73M	12.07M	21.3M	14.41M	16.3M	21.39M	14.94M
Cash Only	13.16M	26.73M	12.07M	21.3M	14.41M	16.3M	21.39M	14.94M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	473K	48K	5.47M	1.85M	3.41M	5.36M
Days Sales Outstanding	-	-	180.03	449.23	91.47	31.81	39.35	50.16
Inventory	0	0	380K	1.24M	550K	557K	911K	15.23M
Days Inventory Outstanding	-	-	306.18	1.59K	76.53	29.32	31.43	356.39
Other Current Assets	0	0	1M	0	0	1.29M	0	5.49M
Total Non-Current Assets+	151K	825K	2.06M	1.62M	3.86M	5.03M	4.9M	35.1M
Property, Plant & Equipment	119K	773K	1.28M	1M	219K	260K	150K	209K
Fixed Asset Turnover	-	-	0.75x	0.04x	99.69x	81.73x	210.95x	186.66x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	725K	575K	3.62M	4.75M	4.74M	34.88M
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	32K	52K	61K	40K	21K	12K	12K	12K
Total Assets+	13.44M	28.33M	17.07M	26.32M	27.46M	25.03M	31.74M	76.12M
Asset Turnover	-	-	0.06x	0.00x	0.79x	0.85x	1.00x	0.51x
Asset Growth %	-	1.11%	-0.4%	0.54%	0.04%	-0.09%	0.27%	1.4%
Total Current Liabilities+	793K	2.02M	1.96M	3.79M	4.56M	6.46M	16.24M	19.95M
Accounts Payable	539K	1.42M	575K	2.34M	1.77M	1.77M	1.85M	4.17M
Days Payables Outstanding	15.13K	8.23K	463.3	2.99K	246.86	92.97	63.75	97.5
Short-Term Debt	0	0	0	280K	1.42M	1.03M	5.38M	0
Deferred Revenue (Current)	0	0	-133K	0	0	0	0	0
Other Current Liabilities	0	0	133K	0	0	0	0	15.74M
Current Ratio	16.76x	13.59x	7.65x	6.51x	5.18x	3.10x	1.65x	2.06x
Quick Ratio	16.76x	13.59x	7.45x	6.18x	5.06x	3.01x	1.60x	1.29x
Cash Conversion Cycle	-	-	22.91	-957.17	-78.86	-31.84	7.02	309.05
Total Non-Current Liabilities+	520K	1.42M	4.56M	6.86M	5.28M	5.49M	22K	31.75M
Long-Term Debt	0	0	4.54M	6.76M	5.26M	5.38M	0	29.81M
Capital Lease Obligations	0	0	19K	99K	15K	107K	22K	107K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	520K	0	0	0	0	0	0	1.83M
Total Liabilities	1.31M	2.02M	6.52M	10.66M	9.84M	11.95M	16.26M	51.7M
Total Debt+	0	0	4.56M	7.14M	6.7M	6.52M	5.4M	29.92M
Net Debt	-13.16M	-26.73M	-7.51M	-14.15M	-7.71M	-9.78M	-15.99M	14.98M
Debt / Equity	-	-	0.43x	0.46x	0.38x	0.50x	0.35x	1.22x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-30.50x	-	-	-	-1.30x
Total Equity+	12.13M	26.3M	10.55M	15.66M	17.63M	13.08M	15.48M	24.43M
Equity Growth %	-	1.17%	-0.6%	0.48%	0.13%	-0.26%	0.18%	0.58%
Book Value per Share	0.69	4.10	0.59	0.75	0.70	0.52	0.60	0.94
Total Shareholders' Equity	12.13M	26.3M	10.55M	15.66M	17.63M	13.08M	15.48M	24.43M
Common Stock	6K	18K	18K	24K	25K	25K	26K	27K
Retained Earnings	-8.64M	-45.87M	-64.19M	-92.16M	-94.11M	-103.13M	-104.07M	-107.89M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-19M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.72M	-8.14M	-18.03M	-22.35M	-4.72M	4.82M	6.82M	969K
Operating CF Margin %	-	-	-18.8%	-572.97%	-0.22%	0.23%	0.22%	0.02%
Operating CF Growth %	-	-0.73%	-1.21%	-0.24%	0.79%	2.02%	0.41%	-0.86%
Net Income	-7.16M	-12.74M	-18.32M	-27.97M	-1.96M	-9.02M	-936K	-3.82M
Depreciation & Amortization	13K	63K	447K	651K	462K	1.77M	901K	1.15M
Stock-Based Compensation	2.64M	1.85M	1.89M	2.58M	3.38M	4.22M	3.14M	3.17M
Deferred Taxes	0	0	0	0	-546K	0	0	0
Other Non-Cash Items	1.29M	2.58M	16K	1.39M	148K	189K	184K	1.18M
Working Capital Changes	623K	99K	-2.06M	1.01M	-6.21M	7.66M	3.53M	-698K
Change in Receivables	0	0	-473K	425K	-5.42M	3.62M	-1.56M	-3.12M
Change in Inventory	0	0	-380K	-862K	692K	-7K	-354K	-1.31M
Change in Payables	539K	413K	-377K	1.77M	-570K	-8K	53K	2.32M
Cash from Investing+	-130K	-236K	-1.85M	-50K	-2.56M	-2.79M	-775K	-40.01M
Capital Expenditures	-130K	-236K	-1.1M	-50K	-3.26M	-38K	-775K	-26K
CapEx % of Revenue	-	-	1.14%	1.28%	0.15%	0%	0.02%	0%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	-750K	0	0	-2.75M	0	-9.99M
Cash from Financing+	18M	21.96M	5.2M	31.63M	391K	-134K	-957K	32.59M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	-1.05M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	18M	205K	453K	367K	0	251K	198K	248K
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.85M	-8.38M	-19.87M	-22.4M	-7.98M	2.03M	6.04M	943K
FCF Margin %	-	-	-20.72%	-574.26%	-0.37%	0.1%	0.19%	0.02%
FCF Growth %	-	-0.73%	-1.37%	-0.13%	0.64%	1.25%	1.97%	-0.84%
FCF per Share	-0.28	-1.31	-1.12	-1.07	-0.32	0.08	0.24	0.04
FCF Conversion (FCF/Net Income)	0.66x	0.64x	0.98x	0.80x	2.41x	-0.53x	-7.28x	-0.25x
Interest Paid	0	0	0	0	0	730K	842K	665K
Taxes Paid	0	0	0	0	0	0	247K	82K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-58.99%	-66.3%	-99.42%	-213.41%	-11.74%	-58.75%	-6.56%	-19.16%
Return on Invested Capital (ROIC)	-	-	-1068.61%	-893.18%	-19.62%	-93.75%	-64.13%	-10.01%
Gross Margin	-	-	52.76%	-633.33%	87.99%	67.38%	66.56%	60.01%
Net Margin	-	-	-1910.32%	-71717.95%	-8.95%	-42.45%	-2.96%	-9.8%
Debt / Equity	-	-	0.43x	0.46x	0.38x	0.50x	0.35x	1.22x
Interest Coverage	-	-	-	-30.50x	-	-	-	-1.30x
FCF Conversion	0.66x	0.64x	0.98x	0.80x	2.41x	-0.53x	-7.28x	-0.25x
Revenue Growth	-	-	-	-95.93%	55879.49%	-2.66%	48.9%	23.29%

Revenue by Segment

	2019	2021	2022	2023	2024
Product Sales and Royalties	-	-	-	26.14M	38.51M
Product Sales and Royalties Growth	-	-	-	-	47.31%
License	-	-	-	5.5M	500K
License Growth	-	-	-	-	-90.91%
Licensing Revenue	500K	19M	10M	-	-
Licensing Revenue Growth	-	3700.00%	-47.37%	-	-

Frequently Asked Questions

Growth & Financials

Eton Pharmaceuticals, Inc. (ETON) reported $70.3M in revenue for fiscal year 2024.

Eton Pharmaceuticals, Inc. (ETON) grew revenue by 23.3% over the past year. This is strong growth.

Eton Pharmaceuticals, Inc. (ETON) reported a net loss of $6.7M for fiscal year 2024.

Dividend & Returns

Eton Pharmaceuticals, Inc. (ETON) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

Eton Pharmaceuticals, Inc. (ETON) generated $21.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Eton Pharmaceuticals, Inc. (ETON) 10-Year Financial Performance & Capital Metrics

ETON • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $39M +23.3%
EBITDA -$1M -398.6%
Net Income -$4M -308.4%
EPS (Diluted) -0.15 -311.0%
Gross Margin 60.01% -9.8%
EBITDA Margin -3.72% -304.4%
Operating Margin -6.66% -76.7%
Net Margin -9.8% -231.3%
ROE -19.16% -192.3%
ROIC -10.01% +84.4%
Debt/Equity 1.22 +250.9%
Interest Coverage -1.30

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 109.8%

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high
✗Expensive at 16.3x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y109.83%

3Y21.35%

TTM102.77%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.91%

EPS CAGR

10Y-

5Y-

3Y-

TTM-14.85%

ROCE

10Y Avg-50.51%

5Y Avg-40.95%

3Y Avg-18.02%

Latest-7.25%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	959K	39K	21.83M	21.25M	31.64M	39.01M
Revenue Growth %	-	-	-	-0.96%	558.79%	-0.03%	0.49%	0.23%
Cost of Goods Sold+	13K	63K	453K	286K	2.62M	6.93M	10.58M	15.6M
COGS % of Revenue	-	-	0.47%	7.33%	0.12%	0.33%	0.33%	0.4%
Gross Profit+	-13K	-63K	506K	-247K	19.21M	14.32M	21.06M	23.41M
Gross Margin %	-	-	0.53%	-6.33%	0.88%	0.67%	0.67%	0.6%
Gross Profit Growth %	-	-3.85%	9.03%	-1.49%	78.77%	-0.25%	0.47%	0.11%
Operating Expenses+	7.14M	10.32M	19.11M	26.86M	20.7M	22.58M	22.25M	26.01M
OpEx % of Revenue	-	-	19.92%	688.82%	0.95%	1.06%	0.7%	0.67%
Selling, General & Admin	3.21M	4.69M	7.55M	12.76M	14.47M	18.58M	18.93M	22.75M
SG&A % of Revenue	-	-	7.87%	327.18%	0.66%	0.87%	0.6%	0.58%
Research & Development	3.93M	5.63M	11.55M	14.1M	6.24M	4M	3.32M	3.25M
R&D % of Revenue	-	-	12.05%	361.64%	0.29%	0.19%	0.1%	0.08%
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-7.15M	-10.32M	-18.6M	-27.11M	-1.5M	-8.26M	-1.19M	-2.6M
Operating Margin %	-	-	-19.4%	-695.15%	-0.07%	-0.39%	-0.04%	-0.07%
Operating Income Growth %	-	-0.44%	-0.8%	-0.46%	0.94%	-4.53%	0.86%	-1.18%
EBITDA+	-7.14M	-10.26M	-18.15M	-26.46M	-1.03M	-6.49M	-291K	-1.45M
EBITDA Margin %	-	-	-18.93%	-678.46%	-0.05%	-0.31%	-0.01%	-0.04%
EBITDA Growth %	-	-0.44%	-0.77%	-0.46%	0.96%	-5.28%	0.96%	-3.99%
D&A (Non-Cash Add-back)	13K	63K	447K	651K	462K	1.77M	901K	1.15M
EBIT	-7.16M	-10.32M	-18.6M	-27.11M	-1.5M	-8.26M	-1.19M	-2.6M
Net Interest Income+	0	0	281K	-889K	0	0	0	-2M
Interest Income	52.5K	164K	281K	0	0	0	0	0
Interest Expense	0	0	0	889K	0	0	0	2M
Other Income/Expense	-6K	-2.42M	281K	-859K	-460K	-761K	503K	-1.21M
Pretax Income+	-7.16M	-12.74M	-18.32M	-27.97M	-1.96M	-9.02M	-689K	-3.81M
Pretax Margin %	-	-	-19.1%	-717.18%	-0.09%	-0.42%	-0.02%	-0.1%
Income Tax+	0	0	0	0	0	0	247K	15K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1.36%	1%
Net Income+	-7.16M	-12.74M	-18.32M	-27.97M	-1.96M	-9.02M	-936K	-3.82M
Net Margin %	-	-	-19.1%	-717.18%	-0.09%	-0.42%	-0.03%	-0.1%
Net Income Growth %	-	-0.78%	-0.44%	-0.53%	0.93%	-3.61%	0.9%	-3.08%
Net Income (Continuing)	-7.16M	-12.74M	-18.32M	-27.97M	-1.96M	-9.02M	-936K	-3.82M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.41	-1.99	-1.02	-1.33	-0.08	-0.36	-0.04	-0.15
EPS Growth %	-	-3.85%	0.49%	-0.3%	0.94%	-3.64%	0.9%	-3.11%
EPS (Basic)	-0.41	-1.99	-1.02	-1.33	-0.08	-0.36	-0.04	-0.15
Diluted Shares Outstanding	17.46M	6.42M	17.76M	21.01M	25.21M	25.15M	25.65M	25.89M
Basic Shares Outstanding	17.46M	6.42M	17.76M	21.01M	25.21M	25.15M	25.64M	25.89M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.29M	27.5M	15.01M	24.7M	23.6M	20M	26.84M	41.02M
Cash & Short-Term Investments	13.16M	26.73M	12.07M	21.3M	14.41M	16.3M	21.39M	14.94M
Cash Only	13.16M	26.73M	12.07M	21.3M	14.41M	16.3M	21.39M	14.94M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	473K	48K	5.47M	1.85M	3.41M	5.36M
Days Sales Outstanding	-	-	180.03	449.23	91.47	31.81	39.35	50.16
Inventory	0	0	380K	1.24M	550K	557K	911K	15.23M
Days Inventory Outstanding	-	-	306.18	1.59K	76.53	29.32	31.43	356.39
Other Current Assets	0	0	1M	0	0	1.29M	0	5.49M
Total Non-Current Assets+	151K	825K	2.06M	1.62M	3.86M	5.03M	4.9M	35.1M
Property, Plant & Equipment	119K	773K	1.28M	1M	219K	260K	150K	209K
Fixed Asset Turnover	-	-	0.75x	0.04x	99.69x	81.73x	210.95x	186.66x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	725K	575K	3.62M	4.75M	4.74M	34.88M
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	32K	52K	61K	40K	21K	12K	12K	12K
Total Assets+	13.44M	28.33M	17.07M	26.32M	27.46M	25.03M	31.74M	76.12M
Asset Turnover	-	-	0.06x	0.00x	0.79x	0.85x	1.00x	0.51x
Asset Growth %	-	1.11%	-0.4%	0.54%	0.04%	-0.09%	0.27%	1.4%
Total Current Liabilities+	793K	2.02M	1.96M	3.79M	4.56M	6.46M	16.24M	19.95M
Accounts Payable	539K	1.42M	575K	2.34M	1.77M	1.77M	1.85M	4.17M
Days Payables Outstanding	15.13K	8.23K	463.3	2.99K	246.86	92.97	63.75	97.5
Short-Term Debt	0	0	0	280K	1.42M	1.03M	5.38M	0
Deferred Revenue (Current)	0	0	-133K	0	0	0	0	0
Other Current Liabilities	0	0	133K	0	0	0	0	15.74M
Current Ratio	16.76x	13.59x	7.65x	6.51x	5.18x	3.10x	1.65x	2.06x
Quick Ratio	16.76x	13.59x	7.45x	6.18x	5.06x	3.01x	1.60x	1.29x
Cash Conversion Cycle	-	-	22.91	-957.17	-78.86	-31.84	7.02	309.05
Total Non-Current Liabilities+	520K	1.42M	4.56M	6.86M	5.28M	5.49M	22K	31.75M
Long-Term Debt	0	0	4.54M	6.76M	5.26M	5.38M	0	29.81M
Capital Lease Obligations	0	0	19K	99K	15K	107K	22K	107K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	520K	0	0	0	0	0	0	1.83M
Total Liabilities	1.31M	2.02M	6.52M	10.66M	9.84M	11.95M	16.26M	51.7M
Total Debt+	0	0	4.56M	7.14M	6.7M	6.52M	5.4M	29.92M
Net Debt	-13.16M	-26.73M	-7.51M	-14.15M	-7.71M	-9.78M	-15.99M	14.98M
Debt / Equity	-	-	0.43x	0.46x	0.38x	0.50x	0.35x	1.22x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-30.50x	-	-	-	-1.30x
Total Equity+	12.13M	26.3M	10.55M	15.66M	17.63M	13.08M	15.48M	24.43M
Equity Growth %	-	1.17%	-0.6%	0.48%	0.13%	-0.26%	0.18%	0.58%
Book Value per Share	0.69	4.10	0.59	0.75	0.70	0.52	0.60	0.94
Total Shareholders' Equity	12.13M	26.3M	10.55M	15.66M	17.63M	13.08M	15.48M	24.43M
Common Stock	6K	18K	18K	24K	25K	25K	26K	27K
Retained Earnings	-8.64M	-45.87M	-64.19M	-92.16M	-94.11M	-103.13M	-104.07M	-107.89M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-19M	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.72M	-8.14M	-18.03M	-22.35M	-4.72M	4.82M	6.82M	969K
Operating CF Margin %	-	-	-18.8%	-572.97%	-0.22%	0.23%	0.22%	0.02%
Operating CF Growth %	-	-0.73%	-1.21%	-0.24%	0.79%	2.02%	0.41%	-0.86%
Net Income	-7.16M	-12.74M	-18.32M	-27.97M	-1.96M	-9.02M	-936K	-3.82M
Depreciation & Amortization	13K	63K	447K	651K	462K	1.77M	901K	1.15M
Stock-Based Compensation	2.64M	1.85M	1.89M	2.58M	3.38M	4.22M	3.14M	3.17M
Deferred Taxes	0	0	0	0	-546K	0	0	0
Other Non-Cash Items	1.29M	2.58M	16K	1.39M	148K	189K	184K	1.18M
Working Capital Changes	623K	99K	-2.06M	1.01M	-6.21M	7.66M	3.53M	-698K
Change in Receivables	0	0	-473K	425K	-5.42M	3.62M	-1.56M	-3.12M
Change in Inventory	0	0	-380K	-862K	692K	-7K	-354K	-1.31M
Change in Payables	539K	413K	-377K	1.77M	-570K	-8K	53K	2.32M
Cash from Investing+	-130K	-236K	-1.85M	-50K	-2.56M	-2.79M	-775K	-40.01M
Capital Expenditures	-130K	-236K	-1.1M	-50K	-3.26M	-38K	-775K	-26K
CapEx % of Revenue	-	-	1.14%	1.28%	0.15%	0%	0.02%	0%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	-750K	0	0	-2.75M	0	-9.99M
Cash from Financing+	18M	21.96M	5.2M	31.63M	391K	-134K	-957K	32.59M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	-1.05M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	18M	205K	453K	367K	0	251K	198K	248K
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.85M	-8.38M	-19.87M	-22.4M	-7.98M	2.03M	6.04M	943K
FCF Margin %	-	-	-20.72%	-574.26%	-0.37%	0.1%	0.19%	0.02%
FCF Growth %	-	-0.73%	-1.37%	-0.13%	0.64%	1.25%	1.97%	-0.84%
FCF per Share	-0.28	-1.31	-1.12	-1.07	-0.32	0.08	0.24	0.04
FCF Conversion (FCF/Net Income)	0.66x	0.64x	0.98x	0.80x	2.41x	-0.53x	-7.28x	-0.25x
Interest Paid	0	0	0	0	0	730K	842K	665K
Taxes Paid	0	0	0	0	0	0	247K	82K

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-58.99%	-66.3%	-99.42%	-213.41%	-11.74%	-58.75%	-6.56%	-19.16%
Return on Invested Capital (ROIC)	-	-	-1068.61%	-893.18%	-19.62%	-93.75%	-64.13%	-10.01%
Gross Margin	-	-	52.76%	-633.33%	87.99%	67.38%	66.56%	60.01%
Net Margin	-	-	-1910.32%	-71717.95%	-8.95%	-42.45%	-2.96%	-9.8%
Debt / Equity	-	-	0.43x	0.46x	0.38x	0.50x	0.35x	1.22x
Interest Coverage	-	-	-	-30.50x	-	-	-	-1.30x
FCF Conversion	0.66x	0.64x	0.98x	0.80x	2.41x	-0.53x	-7.28x	-0.25x
Revenue Growth	-	-	-	-95.93%	55879.49%	-2.66%	48.9%	23.29%

Revenue by Segment

	2019	2021	2022	2023	2024
Product Sales and Royalties	-	-	-	26.14M	38.51M
Product Sales and Royalties Growth	-	-	-	-	47.31%
License	-	-	-	5.5M	500K
License Growth	-	-	-	-	-90.91%
Licensing Revenue	500K	19M	10M	-	-
Licensing Revenue Growth	-	3700.00%	-47.37%	-	-

Frequently Asked Questions

Growth & Financials

Eton Pharmaceuticals, Inc. (ETON) reported $70.3M in revenue for fiscal year 2024.

Eton Pharmaceuticals, Inc. (ETON) grew revenue by 23.3% over the past year. This is strong growth.

Eton Pharmaceuticals, Inc. (ETON) reported a net loss of $6.7M for fiscal year 2024.

Dividend & Returns

Eton Pharmaceuticals, Inc. (ETON) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

Eton Pharmaceuticals, Inc. (ETON) generated $21.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.